Ingrid J, et al. Each and every hepatologist, is intimately familiar with the clinical challenges of both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The importance of these two conditions, stages on a continuum that can terminate in end-stage cirrhosis and hepatocellular carcinoma, is such that this year, the Annals published a supplement devoted to NAFLD and NASH. It is well-recognized that NAFLD and NASH are associated with metabolic syndrome, a syndrome incorporating insulin-resistance, obesity, dyslipidemia etc, and are so common that it is estimated that the prevalence in the United States is approaching 30%. Although hepatologists commonly consider the excess mortality of these two conditions in terms of liver disease outcomes, it is important to appreciate that in the milieu of metabolic syndrome, these patients are very unhealthy and are at increased risk of cardiovascular disease, a risk that appears to be increased when the serum liver biochemistry is increased and higher overall mortality in general.
2009-12-04 | 1,257 visitas | Evalua este artículo 0 valoraciones
Vol. 8 Núm.4. Octubre-Diciembre 2009 Pags. 281-282 Ann Hepatol 2009; 8(4)